EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade

Anand Narayanan; Friedrich D Knollmann; Julie Ann S. Walby; Steffany Lim; David R Gandara; Jonathan Riess

doi:10.1016/j.cllc.2018.12.015

EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade

Anand Narayanan, Friedrich D Knollmann, Julie Ann S. Walby, Steffany Lim, David R Gandara, Jonathan Riess

Research output: Contribution to journal › Article

Original language	English (US)
Journal	Clinical Lung Cancer
DOIs	https://doi.org/10.1016/j.cllc.2018.12.015
State	Accepted/In press - Jan 1 2019

Keywords

Atezolizumab
EBV-positive malignancy
Immunotherapy
PD-L1 antibody
Pulmonary lymphoepithelioma-like carcinoma

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.1016/j.cllc.2018.12.015

Cite this

Narayanan, A., Knollmann, F. D., Walby, J. A. S., Lim, S., Gandara, D. R., & Riess, J. (Accepted/In press). EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2018.12.015

@article{2103e50104b745e3800783a46fb75d5c,

title = "EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade",

keywords = "Atezolizumab, EBV-positive malignancy, Immunotherapy, PD-L1 antibody, Pulmonary lymphoepithelioma-like carcinoma",

author = "Anand Narayanan and Knollmann, {Friedrich D} and Walby, {Julie Ann S.} and Steffany Lim and Gandara, {David R} and Jonathan Riess",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/j.cllc.2018.12.015",

language = "English (US)",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier",

}

TY - JOUR

T1 - EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade

AU - Narayanan, Anand

AU - Knollmann, Friedrich D

AU - Walby, Julie Ann S.

AU - Lim, Steffany

AU - Gandara, David R

AU - Riess, Jonathan

PY - 2019/1/1

Y1 - 2019/1/1

KW - Atezolizumab

KW - EBV-positive malignancy

KW - Immunotherapy

KW - PD-L1 antibody

KW - Pulmonary lymphoepithelioma-like carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85060173550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060173550&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2018.12.015

DO - 10.1016/j.cllc.2018.12.015

M3 - Article

C2 - 30679078

AN - SCOPUS:85060173550

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

ER -